Apexigen
863 Mitten Road
Suite 100C
Burlingame
California
94010-1303
United States
Tel: 650-931-6236 ext 502
Fax: 650-931-6235
Website: http://www.apexigen.com/
Email: info@apexigen.com
About Apexigen
Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease mechanisms.While many companies are working to develop antibody therapies based on mouse- or human-derived antibody technologies, Apexigen is pioneering a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies.
Several blockbuster antibody drugs have been developed with existing mouse and human antibody technologies and display libraries. However, the development of the next generation of antibody-based drugs will require capabilities that exceed those of current technologies in order to bind rare or intractable antigen epitopes and to exert novel effects on disease processes. The key to these next generation therapeutics lies in harnessing the inherent advantages of rabbit antibodies, which have been used successfully in research settings for decades. These advantages are the result of rabbit’s ability to generate a much greater diversity of unique high quality antibodies - with high affinity, high specificity and which bind unique antigen epitopes. These attributes enable the discovery of antibodies that are capable of targeting previously unreachable disease mechanisms.
The company’s proprietary platform technology has allowed Apexigen to build a strong and broad pipeline of seven unique humanized monoclonal antibody programs spanning indications including oncology, inflammatory disease and ophthalmology. Of these seven candidates, four are currently the subject of development partnerships with leading life science companies.
Apexigen’s most advanced internal development program, APX005, is a humanized monoclonal antibody targeting the CD40 protein for the treatment of cancers. Apexigen believes that CD40-induced activation of the immune system by APX005 has the potential to treat a variety of difficult to treat cancers, such as pancreatic cancer, and has exhibited potent anti-tumor effects in animal models.
Collaboration is one of Apexigen’s strengths. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform.
87 articles about Apexigen
-
Pyxis Oncology Successfully Completes Acquisition of Apexigen
8/23/2023
Pyxis Oncology today announced the successful completion of its acquisition of Apexigen, Inc. (“Apexigen”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million.
-
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
6/3/2023
Apexigen, Inc. announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with standard-of-care doxorubicin, in patients with advanced soft tissue sarcoma.
-
Pyxis Oncology to Acquire Apexigen
5/24/2023
Pyxis Oncology, Inc. and Apexigen, Inc. announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share.
-
Apexigen Announces Review of Strategic Alternatives and Restructuring
2/27/2023
Apexigen, Inc. today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.
-
Apexigen Announces Approximately $2.8 Million Private Placement Financing
1/24/2023
Apexigen, Inc today announced that it has entered into definitive agreements with new, biotechnology-focused investors for the issuance and sale of an aggregate of approximately 2.0 million shares of its common stock.
-
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
1/19/2023
Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from Phase 2 multicenter clinical trials evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in two poster presentations at the ASCO Gastrointestinal Cancers Symposium.
-
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
11/15/2022
Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma
11/14/2022
Apexigen, Inc. today announced topline data from an ongoing Phase 2 investigator sponsored trial in collaboration with Columbia University, evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with standard of care doxorubicin (dox), in patients with advanced soft tissue sarcoma (STS).
-
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting
11/11/2022
Apexigen, Inc. today announced new data from an ongoing Phase 2 investigator-sponsored trial evaluating intratumoral sotigalimab (sotiga), Apexigen’s CD40 agonist antibody, in combination with systemic pembrolizumab (anti-PD-1 antibody) in first-line metastatic melanoma.
-
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
9/10/2022
Apexigen, Inc. announced the presentation of new data from a Phase 2 multicenter clinical trial evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction cancers.
-
Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Apexigen, Inc. announced that Company’s Management will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference, to be held virtually and in New York, NY from September 12-14, 2022.
-
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
9/5/2022
Apexigen, Inc. a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced the presentation of new data from a Phase 2 clinical trial evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction cancers.
-
Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
8/4/2022
Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that the Company’s Management will participate virtually in the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022.
-
Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company
8/1/2022
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced the closing of its previously announced business combination with Brookline Capital Acquisition Corp., a special purpose acquisition company.
-
Apexigen to Participate in the Brookline Capital Markets Newport Symposium
7/11/2022
Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen’s Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022.
-
Apexigen Announces Board Appointment and New Chair
6/29/2022
Apexigen, Inc., a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced the appointment of Meenu Karson as a member and Chair of Apexigen’s Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair.
-
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
-
Apexigen Appoints William Duke as Chief Financial Officer
6/8/2022
Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately.
-
Apexigen Announces Nature Medicine Publication & ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy
6/6/2022
Apexigen, Inc. announced a peer-reviewed publication of the randomized, three-arm, Phase 2 PRINCE trial in patients with metastatic pancreatic cancer, conducted in collaboration with the Parker Institute for Cancer Immunotherapy, Bristol Myers Squibb and Cancer Research Institute.
-
Apexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB™ Platform-Webinar to be held Monday, May 16th at 8:00 a.m. PT/ 11:00 a.m. ET-
5/9/2022
Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it will host an investor day to provide an overview of its antibody therapeutic pipeline and unique APXiMAB™ platform on Monday, May 16, 2022.